2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-164816
    FITC-SAHA 1160823-10-8 98%
    FITC-SAHA is SAHA (HY-10221) conjugated with fluorescein. SAHA is an inhibitor of histone deacetylase (HDAC). FITC-SAHA can be used in cancer and Alzheimer's disease related research.
    FITC-SAHA
  • HY-164819
    UNC10099984A 1354030-25-3 98%
    UNC10099984A (Compound 6) is a functionally selective ligand for the dopamine D2 receptor, with a Ki value of 4.6 nM and an EC50 value of 6.2 nM for β-arrestin. UNC10099984A can be used for research into central nervous system disorders related to the D2 receptor.
    UNC10099984A
  • HY-164853
    Kanglexin 2228847-12-7 98%
    Kanglexin is an orally active and novel anthraquinone compound. Kanglexin inhibits NLRP3 inflammatory body activation and cell pyroptosis, and has a cardioprotective effect. Kanglexin promotes angiogenesis through FGFR1/ERK signaling pathway and accelerates diabetic wound healing. In addition, Kanglexin has the effect of lipid-lowering and inhibiting the dedifferentiation of vascular smooth muscle cells, and can be used in the study of hyperlipidemia, fatty liver and atherosclerosis.
    Kanglexin
  • HY-164926
    PARP1-IN-33 2640677-68-3 99.87%
    PARP1-IN-33 (Example 6) is a PARP1 inhibitor (IC50: 0.41 nM). PARP1-IN-33 has retinal cytoprotective effect, with an EC50 of 0.02 nM (inhibition on MTS activity of H2O2 induced human retinal pigment epithelial cell).
    PARP1-IN-33
  • HY-165066
    EOS (d18:1/30:0/18:2) 97040-38-5 98%
    EOS (d18:1/30:0/18:2) is a kind ceramide in the outer epidermis.
    EOS (d18:1/30:0/18:2)
  • HY-165497
    Felbinac tris 935886-64-9 98%
    Felbinac tris (4-Biphenylacetic acid tris) is a potent analgesic agent. Felbinac tris metabolized into 4'-hydroxyfelbinac and is excreted via urine and feces. Felbinac tris has the potential for the research of post-operative pain.
    Felbinac tris
  • HY-165677
    C22 Galactosylceramide 74645-25-3 98%
    C22 Galactosylceramide is a sphingolipid present in the central nervous system, exhibiting elevated levels in the spinal cord of mice on a methionine-restricted diet, while not affecting the brain or liver; furthermore, it has been identified in the postmortem hippocampus of Alzheimer's disease patients.
    C22 Galactosylceramide
  • HY-16567S
    Asenapine-13C,d3 hydrochloride 98%
    Asenapine-13C,d3 (hydrochloride) is the 13C- and deuterium labeled Asenapine (hydrochloride). Asenapine hydrochloride, an antipsychotic, is a 5-HT (1A, 1B, 2A, 2B, 2C, 5A, 6, 7) and Dopamine (D2, D3, D4) receptor antagonist with Ki values of 0.03-4.0 nM for 5-HT and 1.3, 0.42, 1.1 nM for Dopamine receptor, respectively.
    Asenapine-13C,d3 hydrochloride
  • HY-16687B
    Eltoprazine dihydrochloride 143485-51-2 98%
    Eltoprazine (DU 28853) dihydrochloride is a 5-HT1A/5-HT1B receptors agonist and a 5-HT2C receptor antagonist. Eltoprazine dihydrochloride shows antiaggressive and anxiogenic effects.
    Eltoprazine dihydrochloride
  • HY-16688B
    RU 24969 hemisuccinate 66611-27-6 98%
    RU 24969 hemisuccinate is a preferential 5-HT1B agonist, with a Ki of 0.38 nM, but also displays appreciable affinity for the 5-HT1A receptor (Ki=2.5 nM), and has low affinity for other receptor sites in the brain. RU 24969 hemisuccinate could decrease fluid consumption and increase forward locomotion.
    RU 24969 hemisuccinate
  • HY-16728A
    Rapastinel acetate 491872-39-0 98%
    Rapastinel acetate (GLYX-13 acetate) is an N-methyl-D-aspartate (NMDA) receptor modulator with long-acting antidepressant activity. Rapastinel acetate exerts its antidepressant effects by enhancing long-term potentiation (LTP) of synaptic transmission. Rapastinel acetate transiently enhances NMDAR-mediated currents in pyramidal neurons in the hippocampus and medial prefrontal cortex by binding to unique sites on the NMDAR complex. Rapastinel acetate significantly enhanced NMDAR-mediated currents at a concentration of 1 μmol/l and significantly reduced the currents at a concentration of 10 μmol/l. The mechanism of action of Rapastinel acetate is related to the reduction of affinity to intracellular calcium inactivation sites, which provides a theoretical basis for enhancing conductance mediated by NMDAR.
    Rapastinel acetate
  • HY-16748A
    Nelonicline citrate 1026136-84-4 98%
    Nelonicline (ABT-126) citrate is an orally active and selective α7 nicotinic receptor agonist with high affinity to α7 nAChRs in human brain (Ki=12.3 nM). Nelonicline citrate is used for the research of shizophrenia and Alzheimer's disease.
    Nelonicline citrate
  • HY-16758A
    Verosudil hydrochloride 1414854-44-6 98%
    Verosudil (AR-12286) hydrochloride is the hydrochloride form of Verosudil (HY-16758). Verosudil hydrochloride is a ROCK inhibitor. Verosudil hydrochloride has equal inhibitory activity against ROCK1 and ROCK2 (Ki: 2 nM). Verosudil hydrochloride is less selective for PKA, PKCT, MRCKA, and CAM2A (Ki: 69 nM, 9322 nM, 28 nM, 5855 nM, respectively). Verosudil hydrochloride increases trabecular outflow capacity to reduce intraocular pressure. Verosudil hydrochloride is useful in the study of glaucoma and ocular hypertension.
    Verosudil hydrochloride
  • HY-167648
    PD 158771 189152-50-9 98%
    PD 158771 is an antipsychotic agent that functions as a partial agonist for D2 /D3 receptors (Ki = 42.0/13.7 nM) and as an agonist for 5-HT1A receptors (Ki = 2.6 nM). PD 158771 can be utilized in antipsychotic research.
    PD 158771
  • HY-167649
    Poskine 585-14-8 98%
    Poskine is an anticholinergic agent and a central nervous system depressant. Poskine can be utilized in research related to Parkinson's disease and travel sickness .
    Poskine
  • HY-167650
    Fletazepam 34482-99-0 98%
    Fletazepam is a benzodiazepine derivative with sedative, anxiolytic and muscle relaxant effects. Fletazepam can be utilized in neurological research.
    Fletazepam
  • HY-167665
    Fluprazine 76716-60-4 98%
    Fluprazine is an anti-corrosive compound with anxiolytic properties. Fluprazine is used in the study of psychiatric disorders.
    Fluprazine
  • HY-167672
    Propizepine 10321-12-7 98%
    Propizepine is a tricyclic antidepressant compound.
    Propizepine
  • HY-167677
    ASP-2205 1334440-09-3 98%
    ASP-2205 is a 5-HT2C receptor agonist (human 5-HT2C receptor, EC50=0.85 nM; rat 5-HT2C receptor, EC50=2.5 nM). ASP-2205 enhances the pudendal nerve-mediated urethral closure reflex through the 5-HT2C receptor, thereby preventing urinary incontinence.
    ASP-2205
  • HY-167687
    (RS)-Minesapride 1184662-02-9 98%
    (RS)-Minesapride is a serotonin receptor agonist, exhibiting potential therapeutic activity for patients with irritable bowel syndrome with predominant constipation (IBS-C).
    (RS)-Minesapride
Cat. No. Product Name / Synonyms Application Reactivity